Factors associated with long-term retention of treatment with Golimumab in a large cohort of patients with rheumatic diseases, with up to 8 years of follow-up
14/08/2023
M. Pombo-Suarez1 , D. Seoane-Mato2 , L. Cea-Calvo3 , F. Diaz-Gonzalez4 , F. Sánchez-Alonso2 , M. Sánchez-Jareño3 , F. J. Manero Ruiz5 , L. Ruiz6 , V. Jovani7 , I. Castrejon8 on behalf of BIOBADASER investigators. 1
EULAR 2022
DOI: 10.1136/annrheumdis-2022-eular.2429
https://ard.bmj.com/content/81/Suppl_1/773